The leading cause of severe respiratory disease and death in young children is Streptococcus pneumoniae (pneumococcus). An estimated one-fifth of global childhood pneumococcal-related deaths occurred in India. The pneumococcal conjugate vaccine (PCV) is a primary prevention tool against pneumococcal disease that is safe and effective and has been in use in many countries. In alignment with the Government of India's rollout of PCV sub-nationally in selected districts and states, this two-year observational study will use a non-interventional, observational prospective study design to evaluate the impact of PCV in 7 sites in India (5 hospitals and 2 community sites) by assessing clinical and serotype-specific outcomes that include hospitalized pneumonia and community pneumococcal carriage. A sub-study to assess the cost of illness of pneumonia will also be conducted. This study is anticipated to provide data to support sustainability of PCV expansion and disease surveillance in India.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pneumonia colonized by vaccine-type Streptococcus pneumoniae
Timeframe: 2 years (2 year period mentioned refers to the duration of the proposed study in total)
Community carriage of vaccine-type Streptococcus pneumoniae
Timeframe: 2 years (2 year period mentioned refers to the duration of the proposed study in total)
Pneumonia and IPD cost of illness
Timeframe: 1 years (1 year period mentioned refers to the duration of the proposed study in total)